MedTrace Logo

Oncoliq: Test for Early Breast Cancer Detection.

NCT04906330 · Status: RECRUITING · Type: OBSERVATIONAL · Enrollment: 500

Last updated 2024-02-28

No results posted yet for this study

Summary

Oncoliq is a novel early breast cancer detection test based on liquid biopsies and microRNAs. This innovative test will allow improving the accuracy of cancer detection which will impact on health, reducing the patient mortality and health costs.

To develop this test, it has been finished the preclinical PHASE I: in laboratory animals; PHASE II: exploratory clinical phase for the discovery of candidate biomarkers in breast cancer patients and PHASE III: clinical validation of biomarkers showing that Oncoliq has 91% of sensitivity.

Currently it is been setting up a "pilot test" for breast cancer to enrol 500 woman volunteers without previous cancer diagnosis that go to the annual medical control. The results of the pilot test will give the accuracy for early breast cancer detection.

Conditions

Interventions

DIAGNOSTIC_TEST

Oncoliq: test for early breast cancer detection.

Oncoliq is a novel early detection breast cancer test based on liquid biopsies and miRNAs. The main advantage of this test is that miRNAs released from the tumor into the bloodstream can be detected in the plasma of patients even when the tumor is undetectable by other methods.

Sponsors & Collaborators

  • Instituto Nacional del Cáncer, Argentina

    collaborator OTHER_GOV

  • Hospital Militar Central Cirujano Mayor Dr. Cosme Argerich

    lead OTHER

Principal Investigators

  • Adriana De Siervi, PhD · IBYME-CONICET

Eligibility

Min Age
50 Years
Max Age
70 Years
Sex
FEMALE
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2021-09-01
Primary Completion
2024-08-01
Completion
2025-08-01

Countries

  • Argentina

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04906330 on ClinicalTrials.gov